How long can Mounjaro be taken — and what happens when you stop?

Why the licence doesn't give you a number, and what guides the decision instead

Unlike some medicines prescribed for a defined course, tirzepatide doesn't come with a twelve-week or twelve-month expiry written into its UK authorisation. The decision about duration sits with your prescriber, informed by how your body is responding. Two things anchor that decision in formal guidance. First, NICE's appraisal of tirzepatide (TA1026) recommends that if someone loses less than 5% of their body weight after six months on the highest dose they can tolerate, continuing treatment should be reviewed. That is a floor, not a ceiling, people who are responding well are not told to stop at month six. Second, the SmPC (the medicine's prescribing summary) positions Mounjaro within a longer programme of dietary change and physical activity rather than as a temporary intervention with a fixed end date.

In practice, prescribers weigh up how much weight you have lost and at what pace, whether side effects remain manageable, whether the dose can be increased further, and whether the conditions that made treatment appropriate in the first place have improved. A quick habit worth building early: note your starting weight and weigh yourself every four weeks on the same scales at the same time of day. That record gives your prescriber real data to work with at each review, rather than an impression.

Questions about the specifics of your own timeline (including how long being on Mounjaro typically looks across different people) are best put directly to a prescriber who knows your history.

What happens when treatment ends, the weight-regain evidence

This is the part of the conversation that a purely commercial weight-loss message might skip. The trial data on stopping tirzepatide is honest and worth understanding. In SURMOUNT-1, participants who reached maintenance then entered a withdrawal phase; a meaningful proportion of the weight lost was regained once the medicine was no longer taken. Semaglutide trials showed a similar pattern. Tirzepatide does not permanently reset appetite; it works while you are taking it, and stopping removes that effect.

This doesn't mean long-term use is automatic, or that stopping is wrong. For some people, the metabolic improvements gained during treatment (better blood glucose, lower blood pressure, reduced strain on joints) persist even if some weight returns. For others, the calculus points toward continuing. The point is that this decision deserves a real conversation rather than a passive drift toward stopping because the pen runs out or the cost feels high. If the financial side is on your mind, it helps to understand how Mounjaro's UK pricing has changed and what that means in practice.

There is also a separate practical question about the medicine itself, how long Mounjaro takes to produce noticeable results is distinct from overall treatment duration, and knowing what a realistic early timeline looks like helps set sensible expectations.

Long-term use in clinical trials, what the evidence covers so far

The headline SURMOUNT-1 trial ran to 72 weeks, with thousands of adults enrolled. The data from that period is robust. Evidence beyond 72 weeks, while accumulating, is not yet as extensive, and it is worth being straightforward about that rather than implying the long-term picture is entirely settled. What the 72-week data does show is that sustained treatment produced substantially larger reductions in body weight than a short course would, and that the dose-escalation schedule (starting at 2.5mg and stepping up over months) was key to tolerability alongside efficacy. The NHS's information on tirzepatide gives a plain-English summary of what the medicine is and how it is taken, which is a useful reference alongside anything a prescriber tells you.

For people asking specifically about the tirzepatide duration question from a slightly different angle (for instance, how long tirzepatide can be taken under UK guidance, or how long you can stay on tirzepatide longer term) the answer stays the same: no published cap, reviewed regularly, guided by response.

How the review process works at a regulated UK pharmacy

A legitimate, GPhC-registered pharmacy does not treat a Mounjaro repeat as an administrative tick. At nume, every repeat order is read by a real prescriber, the same clinical review the first order received. That means your progress, any side effects, and the appropriateness of your current dose are considered each time. It also means that if the evidence suggests treatment should stop, or that a dose adjustment is needed, that happens through the clinical process rather than being left to chance.

The question of how long an opened Mounjaro pen remains usable is a different but related practical matter, one that matters if your routine means you don't always use a pen immediately. On the broader question of treatment direction and weight-loss treatment options, our prescribers are the right people to speak with. If you'd like that conversation, checking your eligibility is straightforward and free.